UPCC 28225 A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects with Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)

Study of Investigational Medication for Colorectal Cancer

Enrolling By Invitation
99 years or below
All
Phase N/A
1 Location

Brief description of study

To learn more about the safety and effectiveness of Telisotuzumab adizutecan (ABBV-400) given to individuals who have been diagnosed with colorectal cancer. Subjects will be asked to complete the following research procedures: electrocardiograms, echocardiograms, blood tests, and urinalysis, including pregnancy tests if you are able to bear children. Additional procedures that are consistent with your standard of care treatment will also be performed.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

This study investigates colorectal cancer. The purpose is to compare the investigational medication with the current standard of care.

The study evaluates the safety and effectiveness of the investigational medication. It focuses on understanding how well the investigational medication works and its safety profile.

  • Who can participate: Eligibility criteria are to be determined. Include age criteria and key eligibility factors once determined.
  • Study details: Participants will take part in tests such as electrocardiograms, echocardiograms, blood tests, and urinalysis. If applicable, a placebo may be used, defined as an inactive substance that looks like the investigational medicine/vaccine but does not contain any medicine.
Updated on 03 Aug 2026. Study ID: 25-2303
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator